Key Points
- Natera insider Solomon Moshkevich sold 3,000 shares at an average price of $414.22, generating $1.24 million. The Rule 10b5-1 transaction reduced his holdings by 2.73% to 106,914 shares.
- Natera shares opened at $410.35, near their 52-week high of $427.47, with a market capitalization of approximately $59.15 billion. The stock’s 50-day and 200-day moving averages were $332.39 and $261.01, respectively.
- The company reported quarterly revenue of $752.75 million, up 37.7% year over year, and an adjusted loss of $0.47 per share that beat estimates. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $341.55.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $414.22, for a total value of $1,242,660.00. Following the completion of the sale, the insider directly owned 106,914 shares in the company, valued at $44,285,917.08. This represents a 2.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Solomon Moshkevich also recently made the following trade(s):
- On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40.
- On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $320.73, for a total value of $962,190.00.
- On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total value of $905,627.80.
- On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $305,900.28.
- On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $263,094.90.
Natera Price Performance
Shares of NTRA stock opened at $410.35 on Friday. The business's fifty day moving average price is $332.39 and its 200 day moving average price is $261.01. Natera, Inc. has a 1-year low of $160.59 and a 1-year high of $427.47. The firm has a market capitalization of $59.15 billion, a PE ratio of -301.73 and a beta of 1.50.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same quarter in the prior year, the business posted ($0.74) earnings per share. Natera's revenue was up 37.7% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc grew its holdings in Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company's stock valued at $337,000 after buying an additional 36 shares during the last quarter. Parallel Advisors LLC increased its position in Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock worth $181,000 after buying an additional 47 shares in the last quarter. Raiffeisen Bank International AG raised its holdings in shares of Natera by 48.5% in the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company's stock worth $41,000 after acquiring an additional 49 shares during the last quarter. First Horizon Corp raised its holdings in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company's stock worth $196,000 after acquiring an additional 51 shares during the last quarter. Finally, Alamea Verwaltungs GmbH raised its holdings in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock worth $515,000 after acquiring an additional 62 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on NTRA. Sanford C. Bernstein began coverage on shares of Natera in a report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price target for the company. Rothschild & Co Redburn started coverage on shares of Natera in a research report on Tuesday, September 8th. They set a "buy" rating and a $385.00 target price on the stock. Royal Bank Of Canada increased their target price on shares of Natera from $350.00 to $460.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Wells Fargo & Company lifted their price target on shares of Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and an average target price of $341.55.
Get Our Latest Stock Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.
Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
